Company intelligence / Profile preview

Synereca Pharmaceuticals

Oklahoma City, Oklahoma, United Statessosnc.gov ↗

Ownership: Private
Development stage: Other

Overview

Synereca developed small molecules to restore or increase the effectiveness of existing antibiotics against multidrug-resistant Gram-negative bacteria. Their lead program focused on compounds that potentiate Colistin without increasing toxicity and demonstrated significant in vitro and in vivo efficacy in preclinical models. Another program targeted RecA inhibition to block bacterial DNA repair and resistance development. No recent clinical results are available; company appears inactive since mid-late 2010s.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeAntibiotic potentiator
Industry: Biotech

Beyond the preview

Go deeper on Synereca Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synereca Pharmaceuticals.

Explore the full profile